Yes, the FDAs black box warning for medullary thyroid carcinoma and MEN 2 syndrome applies to the entire class of GLP-1 receptor agonists, which include liraglutide (Saxeda and Victoza), dulaglutide (Trulicity), semaglutide (Ozempic, Rybelsus, and Wegovy), and tirzepatide (Mounjaro and Zepbound)
Clinical Microbiology Reviews
Mistake 4: not cleaning the vial stoppers Every time you insert a needle through the rubber stopper, it can push surface bacteria into the solution
Off-label and research use in general obesity or metabolic syndrome remains investigational
Semaglutide was removed in February 2025
Moving the red and swollen joint may be difficult